<p>SKOV3 (A, C) and SKOV3/DDP (B, D) cell viability was inhibited in a dose-dependent manner by treatment with cisplatin and doxycycline. E, F showed that co-treatment with cisplatin (1.5 µg/ml and 2.5 µg/ml) and doxycycline (10 µg/ml) had a significant growth inhibition in SKOV3 cells compared with that of cisplatin or doxycycline treated alone. G, H showed that when combined doxycycline (2.5 and 5 µg/ml) with different concentrations of cisplatin, the IC<sub>50</sub> of cisplatin in SKOV3/DDP cells was 3.36 and 2.66 µg/ml respectively. n = 9. *, <i>p</i><0.05; **, <i>p</i><0.01.</p
<p>(A) NSCLC cells were treated with increasing concentrations of cisplatin (0.1 µM–100 µM) for 72 h...
<p>Human (A, B) and murine (C–H) ovarian cancer cells were exposed to cisplatin, olaparib or vehicle...
Supplementary figure 1. Effects of cisplatin on viability of NRK52E cells and HK-2 cells.NRK52E cell...
Background: Detecting a new effective and hypotoxic anticancer drug is an emerging new strategy for ...
<p>(<b>A</b>) RT-PCR analysis of hNOXA expression <i>in vitro</i> after transfection of A2780s cells...
<p>Parent (PT) and cisplatin resistant (CisR) cell lines were treated with increasing concentrations...
<p>Cells were cultured in transwell with indicated doxycycline for 36/DDP cells by 4 and 2 folds res...
<p>CCK-8 cell proliferation assays(n=3) showing that DDP (<b>A</b>) and SAHA (<b>B</b>) treatment of...
<p>The data were obtained by the MTT assay against human lung carcinoma A549, cervix epithelial carc...
Aim: Ovarian cancer is the third most common gynecological malignancy worldwide. However, it has the...
Summary: The in vitro response to cis‐diamminodichloroplatinum (cisplatin) in primary culture of tum...
<p>Reduction of Akt and ERK expression by Akt and ERK siRNA could attenuate the inhibitory effect on...
Drug resistance to chemotherapy occurs in many ovarian cancer patients resulting in failure of treat...
<p>A) Schematic of cisplatin resistance paradigm as described in materials and methods. B) Represent...
<p>A549 tumor cell survival rate analyses after 1 μM, 5 μM, 10 μM, and 25 μM of Cisplatin was admini...
<p>(A) NSCLC cells were treated with increasing concentrations of cisplatin (0.1 µM–100 µM) for 72 h...
<p>Human (A, B) and murine (C–H) ovarian cancer cells were exposed to cisplatin, olaparib or vehicle...
Supplementary figure 1. Effects of cisplatin on viability of NRK52E cells and HK-2 cells.NRK52E cell...
Background: Detecting a new effective and hypotoxic anticancer drug is an emerging new strategy for ...
<p>(<b>A</b>) RT-PCR analysis of hNOXA expression <i>in vitro</i> after transfection of A2780s cells...
<p>Parent (PT) and cisplatin resistant (CisR) cell lines were treated with increasing concentrations...
<p>Cells were cultured in transwell with indicated doxycycline for 36/DDP cells by 4 and 2 folds res...
<p>CCK-8 cell proliferation assays(n=3) showing that DDP (<b>A</b>) and SAHA (<b>B</b>) treatment of...
<p>The data were obtained by the MTT assay against human lung carcinoma A549, cervix epithelial carc...
Aim: Ovarian cancer is the third most common gynecological malignancy worldwide. However, it has the...
Summary: The in vitro response to cis‐diamminodichloroplatinum (cisplatin) in primary culture of tum...
<p>Reduction of Akt and ERK expression by Akt and ERK siRNA could attenuate the inhibitory effect on...
Drug resistance to chemotherapy occurs in many ovarian cancer patients resulting in failure of treat...
<p>A) Schematic of cisplatin resistance paradigm as described in materials and methods. B) Represent...
<p>A549 tumor cell survival rate analyses after 1 μM, 5 μM, 10 μM, and 25 μM of Cisplatin was admini...
<p>(A) NSCLC cells were treated with increasing concentrations of cisplatin (0.1 µM–100 µM) for 72 h...
<p>Human (A, B) and murine (C–H) ovarian cancer cells were exposed to cisplatin, olaparib or vehicle...
Supplementary figure 1. Effects of cisplatin on viability of NRK52E cells and HK-2 cells.NRK52E cell...